Co-Diagnostics Inc
NASDAQ:CODX

Watchlist Manager
Co-Diagnostics Inc Logo
Co-Diagnostics Inc
NASDAQ:CODX
Watchlist
Price: 0.2639 USD -4.35% Market Closed
Market Cap: 16.1m USD

Co-Diagnostics Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Co-Diagnostics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Co-Diagnostics Inc
NASDAQ:CODX
Stock-Based Compensation
$3.3m
CAGR 3-Years
-22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Stock-Based Compensation
$297m
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Stock-Based Compensation
$240m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Stock-Based Compensation
$662m
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
9%
IDEXX Laboratories Inc
NASDAQ:IDXX
Stock-Based Compensation
$58.2m
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
12%
Intuitive Surgical Inc
NASDAQ:ISRG
Stock-Based Compensation
$761.9m
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
16%
No Stocks Found

Co-Diagnostics Inc
Glance View

Market Cap
16.1m USD
Industry
Health Care

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

CODX Intrinsic Value
HIDDEN
Show

See Also

What is Co-Diagnostics Inc's Stock-Based Compensation?
Stock-Based Compensation
3.3m USD

Based on the financial report for Sep 30, 2025, Co-Diagnostics Inc's Stock-Based Compensation amounts to 3.3m USD.

What is Co-Diagnostics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
7%

Over the last year, the Stock-Based Compensation growth was -45%. The average annual Stock-Based Compensation growth rates for Co-Diagnostics Inc have been -22% over the past three years , 7% over the past five years .

Back to Top